With Roche Opting Out, ArQule Uncertain On Plans For E2F Oncology Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Well-capitalized biotech had planned to launch Phase I investigation of E2F molecule in 2009 before Roche’s unexpected decision.